Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 30 June 2011, 10:00 HKT/SGT
Share:
    

Source: A*STAR
Plastic Cell Membranes for Faster and Cheaper Drug Development
- Technology earns a spot as one of the twelve finalists in the Asian Innovation Awards 2011 organised by the Wall Street Journal Asia

SINGAPORE, June 30, 2011 - (ACN Newswire) - Synthetic cell membranes invented at the Institute of Materials Research and Engineering (IMRE), a research institute of Singapore's Agency for Science, Technology and Research (A*STAR), may improve the way we identify and develop drugs by speeding up and reducing the cost of the drug screening process.

The technology earned a spot as one of the twelve finalists in the Asian Innovation Awards 2011 organised by the Wall Street Journal Asia.

#####

They may look and act like natural human cell membranes but the synthetic cell membranes invented by A*STAR's IMRE have more advantages. IMRE's patented synthetic cell membranes can be made-to-order, are easier to maintain in a laboratory environment and do not require the lengthy preparation that comes with working on live cell membranes. The synthetic cell membranes mimic the natural functions of cell membranes, such as interacting with drug molecules and antibodies, which is crucial in the drug discovery process. The innovation also provides a more stable membrane model for a better understanding of the mechanisms of diseases that affect human cells.

A team of researchers led by IMRE's Dr Madhavan Nallani successfully used synthetic materials to mimic biological processes. "We have harnessed natural cellular processes to fabricate a simple yet functional system using engineered materials to mimic the cell membrane and its proteins," said Dr Nallani, the IMRE scientist who invented the synthetic cell membranes. "These artificial cell membranes allow researchers to study interactions between membrane proteins, drugs and other compounds without the hassle of using living materials."

"Cells communicate with each other through membrane proteins. The disruption of this communication mechanism causes diseases like cancer, diabetes and even Parkinson's disease. Understanding the workings of membrane proteins is very crucial in creating medicines to combat these diseases," explained Professor Eva Sinner, a visiting scientist at IMRE who works on biomaterials and is involved in the project.

Current methods of drug testing require living cells, which entail high capital and maintenance costs, as well as specialists to operate sophisticated equipment. IMRE's patented synthetic cell membranes, which are essentially membrane proteins inserted into a stable polymer matrix outside a cellular environment, creates a platform for researchers to work on that both simple to use and easy to maintain.

"This innovation is a classic example of how materials R&D can be applied to biomedical technologies," said Prof Andy Hor, Executive Director of IMRE. "The success of this technology will be a great boost in helping create better drugs faster and more cost effectively."

Dr Nallani is currently looking for partners to commercialise the technology. The invention has direct impact and application in fields like drug discovery, antibody and therapeutics development, and drug delivery, which are collectively worth some US$170 billion dollars*.

* 2Bio Ltd, Liverpool, UK - Technology Validation and Market report on the patented artificial cellular membrane technology, 2010.


About the Institute of Materials Research and Engineering (IMRE)

The Institute of Materials Research and Engineering (IMRE) is a research institute of the Agency for Science, Technology and Research (A*STAR). The Institute has capabilities in materials analysis & characterisation, design & growth, patterning & fabrication, and synthesis & integration. We house a range of state-of-the-art equipment for materials research including development, processing and characterisation. IMRE conducts a wide range of research, which includes novel materials for organic solar cells, photovoltaics, printed electronics, catalysis, bio-mimetics, microfluidics, quantum dots, heterostructures, sustainable materials, atom technology, etc. We collaborate actively with other research institutes, universities, public bodies, and a wide spectrum of industrial companies, both globally and locally. For more information about IMRE, please visit www.imre.a-star.edu.sg.


Contact:
Mr Eugene Low
Manager, Corporate Communications
Materials Research and Engineering (IMRE)
DID: +65 6874 8491
Mobile: +65 9230 9235
Email: loweom@scei.a-star.edu.sg

For technical enquiries, please contact:

Dr Madhavan Nallani
Scientist II
Institute of Materials Research and Engineering (IMRE)
DID: +65 6872 7541
Email: nallanim@imre.a-star.edu.sg



Topic: Research and development
Source: A*STAR

Sectors: Science & Research, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



A*STAR
Dec 6, 2022 14:00 HKT/SGT
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
June 2, 2022 21:00 HKT/SGT
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies
June 2, 2022 21:00 HKT/SGT
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies
Sept 30, 2021 16:00 HKT/SGT
A*STAR and Local SME Work with Vaccination Centres to Deploy AVID System for Filling Syringes
July 31, 2020 08:00 HKT/SGT
Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials
July 24, 2020 17:00 HKT/SGT
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2
Oct 22, 2019 04:00 HKT/SGT
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology
June 28, 2019 08:00 HKT/SGT
Singapore's Drug Development Efforts Given Additional Momentum with National Platforms
Apr 5, 2019 18:00 HKT/SGT
Passing of Dr Sydney Brenner, Nobel Laureate, Renowned Pioneer in Molecular Biology, A*Star Senior Fellow
Jan 21, 2019 13:00 HKT/SGT
Branched-Chain Amino Acids Found to Regulate the Development and Progression of Cancer
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: